Neuropace
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $22,068 | $26,588 | $27,354 | $23,520 |
Gross Profit | 18,048 | 20,578 | 21,168 | 18,132 |
EBITDA | -5,055 | -1,245 | -2,464 | -6,115 |
EBIT | -5,568 | -1,767 | -2,518 | -6,592 |
Net Income | -6,689 | -2,729 | -3,496 | -8,651 |
Net Change In Cash | 22,068 | 26,588 | 27,354 | 23,520 |
Free Cash Flow | -6,017 | 409 | -1,974 | -2,254 |
Cash | 14,779 | 21,692 | 20,648 | 22,857 |
Basic Shares | 33,716 | 32,722 | 33,134 | 32,863 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $99,986 | $79,906 | $65,421 | $45,520 |
Gross Profit | 77,220 | 59,085 | 48,122 | 32,493 |
EBITDA | -14,390 | -16,574 | -22,834 | -36,566 |
EBIT | -16,338 | -18,343 | -24,439 | -39,553 |
Net Income | -21,465 | -27,141 | -32,956 | -47,082 |
Net Change In Cash | 99,986 | 79,906 | 65,421 | 45,520 |
Cost of Revenue | -12,582 | |||
Free Cash Flow | -11,338 | -18,255 | -19,874 | -37,472 |
Cash | 21,692 | 13,430 | 18,058 | 6,605 |
Basic Shares | 32,722 | 29,126 | 25,851 | 24,594 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$0.19 |
2025-12-31 | -$0.08 |
2025-09-30 | -$0.11 |
2025-06-30 | -$0.26 |